---

Anaesthetic Management of Aneurysm Clipping in Subarachnoid Haemorrhage (SAH)

1. Overview & Pre-Operative Assessment

---

2. Pre-Operative Priorities

Timing of Surgery

• Secure the aneurysm as early as possible, ideally within 24 hours to prevent rebleeding, which carries mortality up to 70%.
• Surgical clipping vs. endovascular coiling: endovascular coiling is preferred when morphology is favourable (higher odds of 1-year favourable outcome); some aneurysms are anatomically more suited to clipping.
• There should be no unnecessary delay regardless of modality chosen.

Blood Pressure Management (Unsecured Aneurysm)

• The updated AHA guideline no longer recommends a specific SBP target for unsecured aneurysms.
• Avoid aggressive antihypertensive treatment — hypotension threatens penumbral perfusion.
• Cautious lowering by 15% if BP exceeds 220/120 mmHg is indicated for medical end-organ complications (hypertensive encephalopathy, aortic dissection).
• Avoid blood pressure variability; hemodynamic monitoring is mandatory.

Pre-op Complications to Manage

Cardiac Workup

• 12-lead ECG: look for QTc prolongation, ST changes
• If ECG abnormal: check troponins
• If troponins elevated: echocardiography (assess wall motion, EF)
• Perform echo for any haemodynamic lability or suspected heart failure
• Reserve coronary catheterisation for isolated wall motion abnormalities with rising troponins (coil the aneurysm first if possible)

---

3. Monitoring

Standard Monitors

• 5-lead ECG, SpO₂, ETCO₂
• Temperature (core)

Invasive Monitors (Mandatory)

• Arterial line (pre-induction): beat-to-beat BP monitoring; essential during induction and for managing acute BP changes at skull opening/clipping
• Central venous catheter: vasopressor delivery, volume management, CVP monitoring
• Cardiac output monitoring: guides vasopressor and fluid choices, especially with catecholamine-related cardiomyopathy

Neurological Monitors

• ICP monitoring (EVD / ventriculostomy): gold standard; permits CSF drainage for brain relaxation and ICP management; allows drug delivery into CSF
• EEG / processed EEG: detects seizures, confirms burst suppression for cerebral protection
• Transcranial Doppler (TCD): monitors for vasospasm
• Jugular bulb venous oximetry (SjvO₂): global cerebral oxygenation; SjvO₂ <55% = critical desaturation
• Somatosensory evoked potentials (SSEPs) / Motor evoked potentials (MEPs): real-time ischaemia detection during temporary clipping

---

4. Induction of Anaesthesia

Goals at Induction

1. Aneurysm re-rupture from hypertensive surges (laryngoscopy, intubation)
2. Cerebral ischaemia from hypotension (especially in vasospasm or already raised ICP)

Technique

• Pre-oxygenation is mandatory
• Modified rapid-sequence or controlled induction: titrate carefully to blunt haemodynamic response
• Propofol (1.5–2.5 mg/kg): smooth induction, reduces CMRO₂, lowers ICP
• Fentanyl / remifentanil (1–2 μg/kg): attenuate sympathetic response to laryngoscopy
• Rocuronium or vecuronium: neuromuscular blockade
• Lidocaine IV (1.5 mg/kg): may further blunt ICP rise to intubation
• Avoid succinylcholine in established neurological deficit (risk of hyperkalaemia), though it may be used if rapid intubation is needed
• Maintain MAP close to pre-operative baseline; avoid even transient hypotension

---

5. Airway & Positioning

• Reinforced (armoured) endotracheal tube; avoid kinking with head rotation
• Head is typically elevated 15–30°, turned to the side — confirm ETT position and arterial line zero reference after positioning
• Arterial transducer zeroed at the level of the circle of Willis (external auditory meatus / tragus) to accurately reflect cerebral perfusion pressure

---

6. Maintenance of Anaesthesia

Agent Selection

• Total intravenous anaesthesia (TIVA) with propofol + remifentanil infusion is widely used; avoids cerebral vasodilatation from volatile agents
• Volatile agents (isoflurane, sevoflurane) at low concentrations (≤1 MAC) are acceptable; at higher doses they impair cerebrovascular autoregulation
• Nitrous oxide: generally avoided in neurosurgery — increases CMRO₂, increases CBF, risk of air embolism expansion, and may worsen neurological outcome
• Muscle relaxation: maintained throughout (no movement during microscopy)

Ventilation

• Target PaCO₂ 35–40 mmHg (normocapnia); avoid hypercapnia (dilates cerebral vessels, raises ICP)
• Mild hyperventilation (PaCO₂ 30–35 mmHg) used transiently for brain relaxation or impending herniation — not sustained (causes ischaemia)
• Maintain SpO₂ >98%; hypoxia is severely detrimental to the ischaemic penumbra

Fluid Management

• Isotonic crystalloids (normal saline or PlasmaLyte) preferred; avoid hypotonic solutions (worsen cerebral oedema)
• Maintain euvolemia: prophylactic hypervolemia is no longer recommended
• "Triple-H therapy" (hypertension–hypervolemia–hemodilution) is no longer recommended — associated with harm without demonstrated benefit in RCTs
• Goal-directed fluid therapy during craniotomy (RCT evidence: PMID 33835084) offers advantages over conventional fluid therapy
• Maintain haematocrit >25%

Brain Relaxation (Surgical Field)

• Mannitol 0.5–1 g/kg IV: osmotic diuresis, reduces brain volume
• Hypertonic saline (3% or 23.4%): alternative osmotic agent
• CSF drainage via lumbar drain or ventriculostomy (EVD)
• Head positioning (15–30° elevation)
• Mild hyperventilation (transient)
• Avoid PEEP if possible (impairs cerebral venous drainage)

---

7. Blood Pressure Management — Intraoperative Phases

---

8. Cerebral Protection

Temporary Clipping

• <10 minutes: generally well tolerated
• >20 minutes: significant ischaemia risk

• Barbiturate burst suppression (thiopentone 3–5 mg/kg or propofol bolus): reduces CMRO₂ by up to 60%; standard neuroprotection practice despite lack of definitive RCT evidence
• Pharmacological agents — volatile anaesthetics, propofol, etomidate, lidocaine: preclinical neuroprotective evidence; reduce glutamate release, activate ATP-K⁺ channels, reduce excitotoxic stress
• Induce mild hypertension (augment collateral flow)
• EEG/SSEP monitoring to detect ischaemia in real time

Hypothermia

• Mild intraoperative hypothermia is NOT recommended for aneurysm clipping.
• The IHAST (Intraoperative Hypothermia for Aneurysm Surgery Trial) demonstrated no improvement in neurologic outcome with mild total-body hypothermia vs. normothermia, but higher rates of infectious complications in the hypothermia group.
• Hyperthermia must be avoided: cerebral ischaemic infarct size triples for each 1°C rise in core temperature. Maintain normothermia actively.

Rapid Ventricular Pacing (RVP)

• Used as an adjunct to reduce aneurysm wall tension transiently during clipping, particularly for large/giant aneurysms
• Requires pacing catheter placement pre-operatively; coordinated with surgical team

---

9. Management of Intraoperative Rupture

1. Immediate communication with surgeon
2. Brief controlled hypotension (MAP 40–50 mmHg): nitroprusside, volatile deepening — only enough to assist clip placement
3. Rapid volume resuscitation and vasopressors once clip is applied
4. Maintain CPP post-clipping to prevent ischaemia
5. Blood products on hand (packed RBCs, FFP); transfuse as needed

---

10. Nimodipine

• Oral nimodipine 60 mg every 4 hours for 21 days is standard care for all aSAH patients.
• Only Level I RCT evidence in SAH demonstrating modest reduction in ischaemic deficits.
• Mechanism: calcium channel blockade (neuroprotective rather than vasodilatory in this context).
• Begin as soon as possible after diagnosis.
• Note: intravenous nimodipine causes significant hypotension; IV route requires careful titration and haemodynamic monitoring.

---

11. Post-Operative Care (ICU)

Vasospasm & Delayed Cerebral Ischaemia (DCI)

• Vasospasm peaks days 5–14 after SAH
• Monitoring: serial clinical exams, TCD, CT perfusion, angiography, cEEG, invasive monitors
• Modified Fisher Grade 4 (bilateral thick SAH + IVH): highest vasospasm risk
• Treatment of DCI: euvolemia (± mild hypervolemia), vasopressors to augment MAP, cardiac output monitoring
• Refractory DCI: intra-arterial vasodilators (verapamil, nicardipine) or balloon angioplasty

General ICU Management

---

12. Summary Algorithm

Pre-op: Grade (H&H, WFNS, Fisher) → Cardiac workup (ECG, echo, troponin)
        → Control BP (avoid extremes) → Nimodipine → Treat hydrocephalus/seizures

Induction: Art line pre-induction → Smooth induction (propofol + opioid)
           → Blunt laryngoscopy response → Maintain baseline MAP

Maintenance: TIVA or low volatile → Normocapnia → Euvolemia → Normothermia
             → Mannitol/CSF drainage for brain relaxation

Temporary clip: Burst suppression (thiopentone) → Mild hypertension
                → EEG/MEP monitoring → Limit <10 min when possible

Post-clipping: Allow hypertension → Vasospasm prophylaxis (nimodipine)
               → ICU monitoring (TCD, cEEG) → DCI protocol if needed

---

• Miller's Anesthesia, 10e — Chapter 80: Subarachnoid Hemorrhage, Management Strategies (pp. 12014–12020)
• Barash Clinical Anesthesia, 9e — Hypothermia / Cerebral Protection section (pp. 3087–3088)
• IHAST Trial: No benefit of mild intraoperative hypothermia for aneurysm clipping (Barash, p. 3088)
• AHA/ASA SAH Guidelines: Nimodipine as only Level I evidence intervention; Triple-H no longer recommended
• Goal-directed fluid therapy RCT during aneurysm clipping (PMID 33835084)
• Intraoperative BP and CO₂ during aneurysmal repair (PMID 37685555)

---

Continuation: Deeper Topics in Anaesthetic Management of Aneurysm Clipping in SAH

---

13. Premedication & Pre-Induction Preparation

Sedation

• Most conscious patients with normal ICP are sedated after aneurysm rupture to prevent rebleeding from agitation, coughing, or hypertensive surges. Continue this sedation until induction of anaesthesia.
• Patients with elevated ICP should receive little or no premedication — opioids, benzodiazepines, and other sedatives risk hypoventilation → hypercapnia → further ICP rise, which can be fatal.

Preparation Before Skin Incision

• Blood must be immediately available in the operating room before aneurysm surgery begins. Exsanguinating haemorrhage from sudden rupture or rebleeding is a real possibility.
• Ensure large-bore IV access (2 peripheral + CVC or trauma line).
• Confirm availability of vasopressors (noradrenaline, phenylephrine, vasopressin) and antihypertensives (labetalol, esmolol, hydralazine, nitroprusside, nicardipine).
• Calcium channel blocker, ACE inhibitor, and ARB users: particularly prone to severe hypotension due to systemic vasodilation and reduced SVR — anticipate and pre-treat.

---

14. ICP and Brain Relaxation — Detailed Considerations

Why ICP Matters in SAH

• Acute hydrocephalus (blood blocking CSF absorption at arachnoid granulations)
• Cerebral oedema (early brain injury mechanisms)
• Intracranial haematoma (IVH, ICH)

Critical Principle — Dural Opening Timing

• Rapid ICP reduction before dural opening must be avoided. A sudden drop in ICP removes the tamponade effect on the aneurysm dome and may precipitate rebleeding.
• Therefore: mannitol and aggressive hyperventilation are timed after dural opening or at least after the surgical field is exposed and controlled.
• Once dura is opened: mannitol is routinely given to facilitate surgical exposure, reduce brain bulk, and decrease retraction pressure on surrounding cortex.

CPP Targets

• Maintain CPP 70–110 mmHg throughout.
• Vasodilating antihypertensives (nitroprusside, hydralazine) should be avoided until the dura is opened — they may cause cerebral vasodilation and ICP spike.
• Preferred antihypertensives before dural opening: labetalol, esmolol, nicardipine (do not increase ICP).

---

15. Grading Tables (Full Detail)

Hunt & Hess Scale

World Federation of Neurological Surgeons (WFNS) Scale

Fisher Scale (CT-based, vasospasm prediction)

Highest vasospasm risk: Modified Fisher Grade 4 (bilateral thick SAH + IVH). TCD velocities >200 cm/s = severe spasm. Lindegaard ratio >3 (MCA velocity / cervical ICA velocity) is also diagnostic of severe vasospasm.

---

16. Neurogenic Cardiac Injury — Deep Dive

ECG Abnormalities (~70% of SAH patients)

• ST elevation/depression
• T-wave inversion
• Pathological Q-waves
• Peaked inverted T-waves (deep, symmetrical T-wave inversions)
• QTc prolongation — most common in SAH compared to all other stroke syndromes
• Hypokalemia (common in SAH) further prolongs QTc → risk of Torsades de Pointes
• Bradycardias (sinoatrial block, AV block) in ~10%
• Life-threatening arrhythmias: VT/VF reported

Neurogenic Stunned Myocardium / Takotsubo Cardiomyopathy

• Reversible syndrome of apical LV dysfunction from catecholamine excess
• Women at higher risk for myocardial necrosis
• Troponin elevation + echocardiographic LV dysfunction in a significant proportion
• Patients with poorer neurological grade (H&H IV–V) have higher peak troponin levels
• Manifests as impaired contractility, reduced EF — haemodynamic instability intraoperatively

Neurogenic Pulmonary Oedema

• Dual mechanism:
  1. Cardiogenic component: systemic hypertension + LV dysfunction → elevated pulmonary venous pressure
  2. Neurogenic component: increased pulmonary capillary permeability (non-cardiogenic leak)
• Can present acutely post-haemorrhage; may worsen with induction of anaesthesia

Anaesthetic Implications

• Beta-blockers (esmolol, labetalol) are preferred agents — reduce myocardial damage and control both SVT and ventricular arrhythmias
• Avoid QT-prolonging drugs (haloperidol, droperidol, ondansetron in high doses, certain antibiotics)
• Correct hypokalemia and hypomagnesemia before surgery

---

17. Vasospasm & Delayed Cerebral Ischaemia — Full Mechanistic Detail

Pathophysiology (Beyond Simple Vasospasm)

1. Cerebral artery vasospasm (smooth muscle contraction from oxyhemoglobin products, endothelin, NO depletion) — classical mechanism
2. Cortical Spreading Depolarisations (CSDs): waves of neuronal depolarisation across grey matter → impaired perfusion in injured brain. NMDA receptor antagonists (e.g., ketamine) may modulate CSDs — an emerging therapeutic rationale
3. Microthrombosis: SAH activates platelets → microthrombi → focal ischaemia
4. Microcirculatory constriction independent of large-vessel vasospasm

Timeline

• Early (0–72 h): rebleeding, hydrocephalus, early brain injury
• Vasospasm peak: days 5–14 post-haemorrhage
• DCI window: days 4–14 (30% of patients)

Monitoring for DCI

Medical Treatment of DCI

• First-line: Euvolemia + MAP augmentation with vasopressors (noradrenaline, phenylephrine); cardiac output monitoring guides therapy
• Nimodipine: neuroprotective (not anti-vasospasm); only Level I evidence in SAH; 60 mg PO q4h × 21 days
• Triple-H therapy (hypervolemia–hypertension–hemodilution): NO LONGER RECOMMENDED — no RCT evidence of benefit; potential for pulmonary oedema, cardiac strain, electrolyte disturbance
• Endothelin antagonists, magnesium, statins: did not improve outcome in clinical trials despite reducing angiographic vasospasm
• Milrinone (IV or intra-arterial): increases CBF via PDE-III inhibition; not standard but used in some centres
• Refractory DCI → endovascular:
  • Intra-arterial vasodilators: nicardipine, verapamil (effective but transient, <24 h duration)
  • Balloon angioplasty: for proximal large-vessel spasm; durable effect but risk of vessel injury

---

18. Electrolyte Complications — Critical for the Anaesthetist

Hyponatremia (30–40% of SAH patients)

Critical warning: Fluid restriction in SAH patients with CSWS causes hypovolaemia → hypotension → cerebral ischaemia from vasospasm. In SAH, when uncertain between CSWS and SIADH, default to volume replacement, not restriction.

Hypokalemia

• Common in SAH; worsens QTc prolongation → Torsades de Pointes
• Correct aggressively before induction if K⁺ <3.0 mmol/L

Hyperglycaemia

• Worsens ischaemic injury; strict normoglycaemia targets

---

19. Deliberate Hypotension vs. Deliberate Hypertension

Historical Context

• Reduce transmural pressure across the aneurysm dome → prevent rupture
• Decrease bleeding and improve surgical visibility

Current Status

• Largely abandoned as routine practice — CPP reduction risks ischaemia, especially in brain already injured by SAH and vasospasm
• Transiently used only in the specific scenario of intraoperative rupture (brief MAP reduction to 40–50 mmHg to allow haemostasis and clip placement)
• Combination of slight head-up position + volatile anaesthetic enhances hypotensive effect of any agent when needed

Deliberate Hypertension (Post-Clipping)

• Once the aneurysm is secured, permissive or induced hypertension is the strategy
• Vasopressors (noradrenaline, phenylephrine) used to maintain MAP targets
• Goals: maintain CPP and treat DCI

---

20. Special Situations

High-Grade SAH (H&H Grade IV–V)

• Surgery in Hunt & Hess grade IV–V carries very high mortality; timing and advisability are debated
• Anaesthetically: expect severely elevated ICP, haemodynamic instability, cardiac dysfunction
• Ventriculostomy before or immediately after induction may be necessary to decompress acutely
• Anticipate difficult emergence and plan for post-op intubation/ICU

Giant Aneurysms (>25 mm)

• Hypothermic circulatory arrest (deep hypothermia + cardiac bypass) is used rarely for giant basilar artery aneurysms not amenable to standard clipping
• Rapid ventricular pacing (RVP): used increasingly to reduce aneurysm wall tension without circulatory arrest. A temporary pacing catheter (RV) is placed preoperatively. Pacing at 180–220 bpm causes transient cardiac output reduction → aneurysm "deflation" → facilitates clip placement

Ruptured Posterior Circulation Aneurysms

• Basilar apex and posterior communicating artery aneurysms: more technically demanding
• Brainstem proximity → higher ischaemia risk during temporary clipping
• MEP monitoring especially important
• More commonly treated endovascularly

Endovascular Coiling (Aneurysm Suite)

• Heparin anticoagulation required intraoperatively (target ACT per team protocol); plan for protamine reversal
• Radiological contrast — renal protection (hydration), allergy precautions
• Haemodynamic management identical — manipulate BP before and after coil deployment
• Remote location from main theatre: full anaesthetic capability must be available

---

21. Emergence and Extubation

When to Extubate at End of Surgery

• Rapid emergence is strongly preferred in good-grade patients: allows immediate neurological exam in the OR (motor strength, language, pupillary response) to detect new deficits from clip misplacement or ischaemia.
• Blunt the haemodynamic response to emergence: lidocaine IV, remifentanil infusion to extubation, labetalol
• Avoid coughing, bucking — raises ICP acutely → risk of bleeding

Smooth Extubation Strategies

• Deep extubation is generally not recommended in neurosurgical patients (loss of airway)
• Remifentanil infusion continued to extubation ("awake smooth extubation")
• Dexmedetomidine (1 μg/kg bolus or low infusion) reduces emergence agitation without respiratory depression

---

22. Post-Operative ICU — Extended Management

Multimodality Monitoring

• cEEG: non-convulsive seizures occur in 20–30%; also early DCI detection via background slowing
• TCD: serial daily monitoring for vasospasm
• CT perfusion / DSA: when TCD equivocal or clinical deterioration
• Brain tissue O₂ (Licox): PbtO₂ <20 mmHg triggers intervention
• ICP/CPP: EVD (already placed in high-grade patients) → target CPP >60 mmHg

Temperature Management

• Fever is independently associated with poor neurological outcome in SAH
• Aggressive normothermia: surface cooling blankets, intravascular cooling catheters if necessary
• Avoid hyperthermia at all costs — even 1°C rise triples ischaemic infarct volume

Analgesia & Sedation in ICU

• Goal: adequate analgesia without respiratory depression or masking of neurological signs
• Paracetamol + low-dose opioids (PRN morphine/fentanyl)
• Avoid NSAIDs (platelet function concern, risk of rebleeding)
• Propofol infusion for sedation in ventilated patients; allows rapid neurological assessment
• Dexmedetomidine: useful for awake patients with agitation

Seizure Prophylaxis

• Anti-seizure drugs ≤7 days post-SAH
• Levetiracetam preferred (does not worsen cognition)
• Phenytoin contraindicated — associated with worse cognitive outcomes in SAH

---

23. Summary of Key Evidence Updates

---

• Morgan & Mikhail's Clinical Anesthesiology, 7e — Chapter 27: Cerebral Aneurysms (pp. 1129–1135)
• Miller's Anesthesia, 10e — Chapter 80: SAH, DCI, Vasospasm Management (pp. 12014–12021)
• Braunwald's Heart Disease — Neurogenic Cardiac Manifestations of SAH (p. 805)
• Adams & Victor's Principles of Neurology, 12e — Cerebral Salt Wasting in SAH
• Beyond nimodipine: advanced neuroprotection in aSAH — Luzzi et al., Neurosurg Rev 2024 (PMID 38967704)
• Current Management of aSAH — 2025 Review — Findlay, Neurol Int 2025 (PMID 40137457)

---

Anaesthetic Management of Aneurysm Clipping in Subarachnoid Haemorrhage (SAH)

---

1. Background & Epidemiology

---

2. Grading Systems

Hunt & Hess Scale

WFNS Scale

Fisher Scale (CT-based, vasospasm prediction)

---

3. Pre-operative Priorities

Timing of Surgery

• Secure the aneurysm as early as possible, ideally within 24 hours to prevent rebleeding (which carries mortality up to 70%).
• Surgical clipping vs. endovascular coiling: coiling preferred when morphology is favourable (higher 1-year favourable outcome); some aneurysms are anatomically more suitable for clipping.
• No delay is acceptable regardless of modality.

Blood Pressure Management (Unsecured Aneurysm)

• Updated AHA guideline: no specific SBP target is recommended.
• Avoid aggressive antihypertensive therapy — hypotension threatens penumbral perfusion.
• Cautious lowering by ~15% if BP exceeds 220/120 mmHg for medical end-organ crises only.
• Avoid blood pressure variability; continuous haemodynamic monitoring mandatory.

Early Complications to Treat Before Surgery

Cardiac Workup — Mandatory

• ECG abnormalities in ~70% of SAH patients: ST changes, T-wave inversion, peaked inverted T-waves, QTc prolongation, pathological Q-waves
• QTc prolongation + hypokalemia → risk of Torsades de Pointes
• Bradycardias (SA block, AV block) in ~10%
• Neurogenic stunned myocardium / Takotsubo cardiomyopathy: reversible apical LV dysfunction; troponin elevated + echo evidence of wall motion abnormality
• Women at higher risk for myocardial necrosis; worse neuro grade → higher troponin
• Neurogenic pulmonary oedema: dual mechanism — cardiogenic (LV dysfunction) + non-cardiogenic capillary leak

1. 12-lead ECG → if abnormal: troponins
2. Troponins elevated → echocardiography
3. Echo for any haemodynamic instability or suspected heart failure
4. Reserve coronary catheterisation for isolated wall motion deficit + rising troponins (coil first if possible)

Premedication

• Conscious patients with normal ICP: sedate to prevent rebleeding from agitation/hypertension; continue until induction.
• Patients with elevated ICP: little or no premedication — sedatives cause hypoventilation → hypercapnia → ICP rise.

---

4. Monitoring

Invasive (All Mandatory)

• Arterial line — placed BEFORE induction: beat-to-beat BP, ABG sampling. Zero the transducer at the level of the Circle of Willis (external auditory meatus/tragus) to reflect true cerebral perfusion pressure.
• Central venous catheter: vasopressor delivery, CVP monitoring
• Cardiac output monitoring: guides vasopressor and fluid choices, especially in neurogenic cardiomyopathy

Neurological

• ICP/EVD: gold standard for ICP; permits CSF drainage for brain relaxation; allows drug delivery into CSF. Absolutely required in high-grade SAH.
• EEG / processed EEG: detects seizures, confirms burst suppression during cerebral protection
• SSEPs / MEPs: real-time ischaemia detection during temporary clipping — critical for posterior circulation aneurysms
• Transcranial Doppler (TCD): vasospasm monitoring; MCA velocity >200 cm/s = severe spasm; Lindegaard ratio >3 = significant spasm
• Jugular bulb oximetry (SjvO₂): global cerebral oxygenation; SjvO₂ <55% = critical cerebral desaturation
• Brain tissue O₂ (PbtO₂): <20 mmHg triggers intervention

Standard

• 5-lead ECG, SpO₂, ETCO₂, temperature (core — maintain normothermia strictly)

---

5. Induction of Anaesthesia

Goals

1. Re-rupture from hypertensive surge at laryngoscopy/intubation
2. Cerebral ischaemia from hypotension (penumbra, vasospasm, raised ICP)

Technique

• Full pre-oxygenation
• Arterial line before induction
• Controlled induction — titrated to blunt haemodynamic response:
  • Propofol 1.5–2.5 mg/kg: reduces CMRO₂, lowers ICP, smooth induction
  • Fentanyl/remifentanil 1–2 μg/kg: attenuates sympathetic response to laryngoscopy
  • Rocuronium/vecuronium: neuromuscular blockade
  • Lidocaine IV 1.5 mg/kg: further blunts ICP rise to intubation
• Avoid succinylcholine in established neurological deficits (hyperkalaemia risk)
• Patients on calcium channel blockers, ACE inhibitors, ARBs are prone to profound hypotension — have vasopressors ready
• Maintain MAP close to pre-operative baseline throughout induction

---

6. Airway & Positioning

• Reinforced (armoured) endotracheal tube — prevents kinking with head rotation
• Head elevated 15–30°, rotated to operative side — confirm ETT position after final positioning
• Re-zero arterial transducer at external auditory meatus after positioning

---

7. Maintenance of Anaesthesia

Agents

Ventilation

• Target PaCO₂ 35–40 mmHg (normocapnia)
• Mild hyperventilation (PaCO₂ 30–35 mmHg): short-term only for acute brain relaxation or impending herniation — not sustained (causes ischaemia)
• SpO₂ >98%; hypoxia devastates ischaemic penumbra

Fluids

• Isotonic crystalloids (normal saline, PlasmaLyte) — no hypotonic solutions (worsen cerebral oedema)
• Maintain euvolemia; prophylactic hypervolemia is no longer recommended
• Goal-directed fluid therapy during craniotomy shows advantages over conventional fluid management (RCT evidence, PMID 33835084)
• Maintain haematocrit >25%; transfusion is controversial — balance O₂ delivery vs. transfusion harm

Brain Relaxation (for Surgical Exposure)

1. Mannitol 0.5–1 g/kg IV (after dural opening)
2. Hypertonic saline (3% or 23.4%) — alternative osmotic agent
3. CSF drainage via EVD or lumbar drain
4. Head-up 15–30°
5. Short-term mild hyperventilation
6. Minimise PEEP (impairs cerebral venous drainage)

Critical: Avoid rapid ICP reduction before dural opening — removes tamponade effect → precipitates rebleeding.

---

8. Intraoperative Blood Pressure Targets by Phase

---

9. Cerebral Protection

Temporary Clipping

• Barbiturate burst suppression: thiopentone 3–5 mg/kg IV bolus (or propofol bolus); reduces CMRO₂ by up to 60%; standard practice despite absence of definitive RCT evidence
• Propofol, etomidate, volatile anaesthetics: reduce glutamate release, activate ATP-K⁺ channels, reduce excitotoxic stress
• Induce mild hypertension: augment collateral flow
• EEG monitoring: confirms burst suppression; detects ischaemia
• SSEP/MEP: real-time ischaemia detection

Hypothermia

• Mild intraoperative hypothermia is NOT recommended.
• IHAST Trial: no neurological benefit from mild hypothermia vs. normothermia during aneurysm clipping; higher rates of infectious complications in hypothermia group.
• Hyperthermia must be strictly avoided: ischaemic infarct volume triples for every 1°C rise in core temperature.
• Actively maintain normothermia with warming blankets, warm IV fluids, temperature monitoring.

Rapid Ventricular Pacing (RVP)

• Adjunct for large/giant aneurysms: temporary RV pacing at 180–220 bpm → transient CO reduction → aneurysm "deflation" → facilitates clip placement
• Requires pre-op RV pacing catheter; fully coordinated team effort

---

10. Management of Intraoperative Rupture

1. Immediately alert surgeon — rapid communication is critical
2. Brief controlled hypotension (MAP 40–50 mmHg): IV nitroprusside, deepen volatile, or nitroglycerin — only enough to facilitate clip placement
3. Rapid volume resuscitation + vasopressors once clip applied
4. Restore and maintain CPP post-clipping to prevent ischaemia
5. Blood products immediately available: packed RBCs, FFP; transfuse as needed

---

11. Nimodipine — The Only Level I Evidence in SAH

• 60 mg PO every 4 hours for 21 days for all aSAH patients
• Start as soon as possible after diagnosis
• Only intervention with Level I RCT evidence in SAH: modest reduction in ischaemic deficits
• Mechanism: neuroprotective via calcium channel blockade (not primarily anti-vasospasm)
• IV nimodipine causes significant hypotension — requires careful titration if oral route not possible

---

12. Vasospasm & Delayed Cerebral Ischaemia (DCI)

Pathophysiology (Multifactorial)

1. Cerebral artery vasospasm: oxyhemoglobin products, endothelin, NO depletion → smooth muscle contraction
2. Cortical spreading depolarisations (CSDs): waves of neuronal depolarisation → impaired perfusion in injured brain. NMDA antagonists (ketamine) may modulate CSDs — reassessment of ketamine underway
3. Microthrombosis: platelet activation by SAH → focal ischaemia
4. Microcirculatory constriction independent of large vessels

Timeline

• Vasospasm peak: days 5–14
• DCI window: days 4–14 (~30% of patients)

Monitoring for DCI

Treatment of DCI

---

13. Electrolyte Complications

Hyponatremia (30–40% of SAH patients)

Warning: Fluid restriction in SAH with CSWS causes hypovolaemia → hypotension → cerebral ischaemia. When uncertain, default to volume replacement.

Other Electrolytes

• Hypokalemia: correct aggressively before induction (QTc prolongation → TdP)
• Hyperglycaemia: worsens ischaemic injury; target strict normoglycaemia

---

14. Emergence & Extubation

• Remifentanil infusion continued to extubation
• IV lidocaine or labetalol to blunt haemodynamic response
• Dexmedetomidine (reduces emergence agitation without respiratory depression)
• Avoid coughing/bucking — acute ICP rise → risk of rebleeding

---

15. Post-Operative ICU Management

---

16. Key Evidence — What Changed

---

17. Summary Clinical Algorithm

PRE-OP
├── Grade: Hunt & Hess + WFNS + Fisher CT
├── Cardiac: ECG → troponins → echo if abnormal
├── Control BP (avoid extremes; no specific SBP target)
├── Start nimodipine 60 mg q4h PO
├── Treat hydrocephalus (EVD), seizures (levetiracetam), correct K⁺
└── Blood available in OR; large-bore IV access

INDUCTION
├── Arterial line before induction (zeroed at EAM)
├── Propofol + remifentanil/fentanyl + rocuronium ± lidocaine
├── Blunt laryngoscopy response
└── Maintain MAP near pre-op baseline

MAINTENANCE
├── TIVA preferred (propofol + remifentanil) or low volatile (≤1 MAC)
├── Normocapnia (PaCO₂ 35–40 mmHg)
├── Isotonic fluids; euvolemia; Hct >25%
├── Normothermia strictly (active warming)
└── Mannitol + CSF drainage after dural opening

TEMPORARY CLIP
├── Burst suppression (thiopentone 3–5 mg/kg)
├── Mild induced hypertension
├── EEG + MEP/SSEP monitoring
└── Limit duration < 10 min when possible

POST-CLIPPING
├── Discontinue burst suppression
├── Allow/induce hypertension (vasopressors)
├── Smooth emergence if H&H I–III; otherwise remain intubated
└── Immediate neurological exam in OR before ICU transfer

ICU
├── Multimodality monitoring (TCD, cEEG, PbtO₂)
├── Vasospasm surveillance days 5–14
├── DCI: euvolemia + MAP augmentation (not Triple-H)
└── Nimodipine continue × 21 days total

---

• Miller's Anesthesia, 10e — Ch. 80: SAH & DCI Management
• Morgan & Mikhail's Clinical Anesthesiology, 7e — Ch. 27: Cerebral Aneurysms
• Barash Clinical Anesthesia, 9e — Hypothermia & Cerebral Protection (IHAST)
• Braunwald's Heart Disease — Neurogenic Cardiac Manifestations of SAH
• Adams & Victor's Principles of Neurology, 12e — Cerebral Salt Wasting
• Current Management of aSAH — Findlay, Neurol Int 2025 (PMID 40137457)
• Beyond nimodipine: advanced neuroprotection in aSAH — Luzzi et al., Neurosurg Rev 2024 (PMID 38967704)
• Goal-directed fluid therapy in aneurysm clipping RCT (PMID 33835084)